|
|
|
| Exploration of Efficacy of Golimumab Combined with Leflunomide in the treatment of Active RA with Poor MTX Efficacy |
| PAN Lu, ZHAO Hua, et al |
| West China Nursing College, West China Hospital of Sichuan University, Sichuan Chengdu 610041, China |
|
|
|
|
Abstract Objective: To study the effects of golimumab combined with leflunomide in the treatment of active rheumatoid arthritis (RA) with poor treatment effects of methotrexate (MTX). Methods: 70 patients with active RA with poor MTX treatment effects in the hospital from December 2016 to December 2018 were divided into observation group (golimumab +leflunomide, n=35) and control group (leflunomide, n=35) according to the simple random grouping. The treatment effects were observed in the two groups. Results: After treatment, the morning stiffness time in the two groups was significantly shortened, and the quantities of joint swelling and tenderness were significantly decreased (P<0.05), and the morning stiffness time and quantities of joint swelling and tenderness in observation group were significantly shorter/Less than those in control group (P<0.05). After treatment, the visual analogue pain scale (VAS) scores of patients and doctors in the two groups were significantly lower than those before treatment (P<0.05), and the VAS scores of patients and doctors in observation group after treatment were significantly lower than those in control group (P<0.05). After treatment, the levels of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and rheumatoid factor (RF) were significantly lower than those before treatment (P<0.05), and the levels of above substances in observation group were significantly lower than those in control group (P<0.05). After treatment, the levels of serum interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), plasma fibrin/fibrinogen degradation product (FDP) and D-dimer (DD) were significantly lower than those before treatment (P<0.05), and the levels of above substances in observation group after treatment were significantly lower than those in control group (P<0.05). The proportions of ARC50 and ARC70 in observation group were significantly higher than those in control group (P<0.05). There were no significant differences in the adverse drug reactions between the two groups (P>0.05). Conclusion: Golimumab combined with leflunomide has good treatment effects in active RA patients with poor MTX treatment effects. And it can effectively alleviate clinical symptoms such as morning stiffness, joint swelling and tenderness, reduce the levels of ESR, CRP, RF and serum-related inflammatory substances, and improve the treatment effects, and it does not increase the adverse reactions, thus it is worthy of clinical promotion.
|
|
|
|
|
|
[1] 王鑫,赵琴,邓肇达,等.老年类风湿性关节炎治疗进展[J].中国骨伤,2017,30(6):576~580.
[2] 孙青,谢瑶,赵卫红,等.大剂量甲氨蝶呤治疗毒副作用系统分析[J].中国当代儿科杂志,2017,19(7):781~785.
[3] 刘婧依,陈赵玲,刘歧焕,等.戈利木单抗联合雷公藤多甙对甲氨蝶呤治疗反应不佳活动性类风湿关节炎的效果及安全性分析[J].现代生物医学进展,2017,17(9):1735~1738,1725.
[4] 吕芳,李兴福.2010年美国风湿病学会联合欧洲抗风湿病联盟的类风湿关节炎分类标准解读[J].诊断学理论与实践,2010,9(4):307~310.
[5] 中华医学会风湿病学分会.2018中国类风湿关节炎诊疗指南[J].中华内科杂志,2018,57(4):242~251.
[6] 吴吉荣.类风湿关节炎遗传易感性研究进展[J].河北医科大学学报,2017,38(9):1103~1108.
[7] 郭明慧,吕爽,黄晶,等.来氟米特治疗类风湿关节炎药物基因组学研究进展[J].中华风湿病学杂志,2018,22(5):334~336.
[8] 杨茹,张祎,刘志纯.甲氨蝶呤联合来氟米特治疗类风湿关节炎效果观察[J].山东医药,2018,58(6):91~92.
[9] 王瑞萍.类风湿关节炎患者血清中抗CCP抗体和TNF-α表达的临床意义[J].重庆医学,2017,46(12):1624~1625,1628.
[10] 李岩异,张卫婷.IL-6:TNF-α之后的类风湿关节炎治疗关键靶点[J].生物工程学报,2017,33(1):36~43. |
|
|
|
2020, Vol. 26 
